- A single-dose gene therapy using an engineered adenovirus that expresses anti-methamphetamine monoclonal antibodies protected mice for more than eight months by sequestering meth in serum and preventing CNS entry, pointing toward a possible clinical treatment for human stimulant addiction.  
- A fully open-source, <$500 multi-fluorescence microscope platform published in PLOS ONE is intended to democratize advanced imaging for biology education and DIY bioengineering labs worldwide.  
- George Church’s NEJM editorial frames human germline editing as a logical extension of accepted inter-generational health interventions (e.g., vaccines) and calls for equitable global access; MIT Tech Review’s Antonio Regalado labels the position “Eugenics 2.0,” sparking debate on responsible enhancement.  
- A Nature Biotechnology paper reports highly efficient, non-viral in vivo CRISPR editing achieved by chemically modified guide RNAs delivered via optimized lipid nanoparticles, moving therapeutic gene correction toward safer, non-integrating modalities.  
- An Amish kindred carrying a loss-of-function SERPINE1 (PAI-1) mutation exhibits longer telomeres, improved insulin sensitivity, and apparent protection against multiple age-related pathologies, offering a naturally occurring longevity model.  
- Acceleron’s myostatin inhibitor ACE-2494 failed in bacterial expression and shows immunostimulatory side-effects; a recent patent combines it with PD-L1 blockade to exploit its immune-activating properties for oncology applications.  
- Channel members floated the idea of engineering male lactation through targeted genetic modification—discussed both as a practical childcare innovation and as a provocative media demonstration to normalize human genetic engineering.  
- A meta-analysis circulated on Twitter shows that single-blind peer review significantly favors manuscripts from high-status authors and institutions, whereas double-blind review removes most of this bias, reinforcing calls for reform in scientific publishing.